Drug Profile
Research programme: neuroprotective protein - Evive Biotech
Alternative Names: F-637Latest Information Update: 01 Oct 2020
Price :
$50
*
At a glance
- Originator Generon (Shanghai) Corporation
- Developer Evive Biotech
- Class Neuroprotectants; Recombinant fusion proteins
- Mechanism of Action Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 01 Oct 2020 Evive Biotech has been acquired by Yifan Pharmaceutical
- 16 Jul 2016 No recent reports of development identified for preclinical development in Stroke in China (Parenteral)
- 04 May 2012 Preclinical trials in Stroke in China (Parenteral)